The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum

Nicole Seidel, Xandra Volkmann, Florian Länger, Peer Flemming, Michael P. Manns, Klaus Schulze‐Osthoff, Heike Bantel – 26 May 2005 – Hepatic steatosis is a frequent histological alteration in chronic hepatitis C virus (HCV) infection that sensitizes the liver to cell injury, inflammation, and fibrosis via unclear mechanisms. Although apoptosis has been implicated in various liver diseases, its importance in HCV‐associated steatosis is largely unknown.

Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice

Daniel Benten, Antonia Follenzi, Kuldeep K. Bhargava, Vinay Kumaran, Christopher J. Palestro, Sanjeev Gupta – 25 May 2005 – Targeting of cells to specific tissues is critical for cell therapy. To study endothelial cell targeting, we isolated mouse liver sinusoidal endothelial cells (LSEC) and examined cell biodistributions in animals.

A functional polymorphism in the IL‐10 promoter influences the response after vaccination with HBsAg and hepatitis A

Thomas Höhler, Esther Reuss, Christine M. Freitag, Peter M. Schneider – 25 May 2005 – The immune response to hepatitis B surface antigen (HBsAg) is mostly genetically determined. Interleukin 10 (IL‐10) is a central immunoregulatory cytokine with important effects on B‐cells. We have studied the influence of IL‐10 promoter polymorphisms on the immune response to HBsAg and hepatitis A vaccination. We vaccinated 202 twin pairs in an open prospective study with a combined recombinant HBsAg/inactivated hepatitis A vaccine.

A murine model of acute liver injury induced by human monoclonal autoantibody

Katsumi Yamauchi, Naoko Yamaguchi, Takaji Furukawa, Kazuko Takatsu, Toshimi Nakanishi, Kohji Ishida, Tatsuji Komatsu, Katsutoshi Tokushige, Hikaru Nagahara, Etsuko Hashimoto, Keiko Shiratori – 25 May 2005 – We have previously reported an immunoglobulin (Ig) M autoantibody to hepatocyte‐related 190‐kd molecules in patients with type 1 autoimmune hepatitis (AIH). This molecule was first isolated by hepatocyte‐specific human monoclonal antibody (MoAb).

A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue

Jeremy J. Theal, Mohssen N. Toosi, Larisa Girlan, Ronald J. Heslegrave, Pierre‐Michel Huet, Kelly W. Burak, Mark Swain, George A. Tomlinson, E. Jenny Heathcote – 24 May 2005 – Fatigue is common in primary biliary cirrhosis (PBC). Altered central serotonergic neurotransmission may be involved in its pathogenesis. This multicenter, randomized, double‐blind, placebo‐controlled, crossover trial evaluated the efficacy of ondansetron, a selective 5‐HT3 receptor subtype antagonist, for treating fatigue in PBC.

Subscribe to